Clinical Study on the Use of Dexmedetomidine Compound with Bupivacaine Liposomes for Fascia Iliaca Compartment Block in Postoperative Pain Management Following Hip Replacement Surgery in the Elderly

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2600121044

Enrollment

Unknown

Registered

2026-03-24

Start date

2026-03-24

Completion date

Unknown

Last updated

2026-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Experimental group:Bupivacaine Liposome 266mg + Dexmedetomidine 1µg/kg + Normal Saline diluted to 30mL for fascia Iliaca compartment block

Control group:Bupivacaine Liposome 266mg + Normal Saline diluted to 30mL for fascia Iliaca compartment block

Eligibility

Sex/Gender

All

Age

65 Years to 100 Years

Inclusion criteria

Inclusion criteria: 1. Age>=65 years, no gender restrictions; 2. Patients meeting diagnostic criteria for hip replacement surgery; 3. Complete documentation available; 4. All patients meet anesthesia and surgical indications; 5. No psychiatric disorders or cognitive impairment; 6. All patients were informed of the study details prior to enrollment and voluntarily signed informed consent forms.

Exclusion criteria

Exclusion criteria: 1. Individuals with analgesic drug dependence; 2. History of chronic pain or neurological disorders; 3. Impaired cardiac, hepatic, or renal function; 4. Allergy to anesthetic agents; 5. Active infections (e.g., pneumonia) or uncontrolled conditions (e.g., diabetic ketoacidosis, post-cerebral infarction sequelae); 6. Patients who have participated in other clinical trials within the past week; 7. Any condition deemed by the investigator to be unstable or potentially compromising the subject's safety or compliance with the study; 8. History of allergy to the study drug or excipients, or previous severe adverse reactions; 9. Patients with psychiatric disorders or social/geographic conditions that may interfere with adherence to the study protocol and follow-up schedule.

Design outcomes

Primary

Measure	Time frame
Pain intensity at rest and during exercise;	—

Secondary

Measure	Time frame
The dosage of sufentanil;Number of effective compressions for the analgesic pump;Number of patients requesting additional analgesia;Incidence of postoperative adverse reactions;Time of first ambulation after surgery;Time to spontaneous breathing;Extubation time;Wake-up time;Total number of postoperative activities;Total length of postoperative hospital stay;	—

Countries

China

Contacts

Public ContactYou Shuyong

Luxian People's Hospital

2830987117@qq.com+86 182 8113 6423

Outcome results